United Therapeutics Corporation (UTHR)

Return on assets (ROA)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	984,800	899,800	871,500	728,300	727,300	707,400	630,800	687,400	475,800	462,400	470,900	405,400	514,800	698,300	659,500	757,500	125,200	192,400	166,500	134,300
Total assets	US$ in thousands	7,167,000	7,023,600	6,681,300	6,346,000	6,044,500	5,781,600	5,543,300	5,359,800	5,169,100	5,048,900	4,844,900	4,641,000	4,615,000	4,411,200	4,219,400	4,025,900	3,913,400	3,999,600	3,898,900	3,726,700
ROA		13.74%	12.81%	13.04%	11.48%	12.03%	12.24%	11.38%	12.83%	9.20%	9.16%	9.72%	8.74%	11.15%	15.83%	15.63%	18.82%	3.20%	4.81%	4.27%	3.60%

December 31, 2023 calculation

ROA = Net income (ttm) ÷ Total assets
= $984,800K ÷ $7,167,000K
= 13.74%

United Therapeutics Corp's Return on Assets (ROA) has shown a generally positive trend over the past eight quarters, with values ranging from 11.38% to 13.74%. ROA measures the company's efficiency in generating profits from its assets, and a higher ROA indicates better asset utilization.

The highest ROA of 13.74% was achieved in Q4 2023, signifying that, during that quarter, United Therapeutics Corp was successful in generating a profit of 13.74 cents for every dollar of assets it owned. This is a positive indicator of the company's operational efficiency and profitability.

It's worth noting that the ROA fluctuated over the quarters, with Q2 2022 showing the lowest ROA at 11.38%. However, the subsequent quarters generally showed an upward trend, with Q4 2023 reaching the highest point. This improvement may suggest that United Therapeutics Corp has been effectively managing its assets to increase profitability.

Overall, the company's ROA performance indicates a positive trend in asset utilization and profitability, with the most recent quarter showing particularly strong results. However, continual monitoring of ROA trends and comparison with industry benchmarks will provide a comprehensive understanding of United Therapeutics Corp's financial health and efficiency in utilizing its assets.